---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-042695"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:48:55.548055+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio FY 2023 net loss $56.2M; cash $5.8M; PD Phase III completed, AD top-line data expected April

## Summary
- Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.
- Cash and equivalents $5.8M as of Dec 31, 2023, down from $28.4M.
- R&D expenses $38.8M for FY 2023, up from $16.5M, driven by AD and PD trial costs.
- PD Phase III completed with 471 patients; AD Phase II/III fully enrolled (353 patients); top-line efficacy data expected in April 2024.
- Appointed Andrew Walsh as VP Finance in December 2023.

## SEC filing metadata
- accession: 0001104659-24-042695
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/0001104659-24-042695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/tm2410669d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-042695
- JSON: https://secwatch.observer/filing/0001104659-24-042695.json
- Plain text: https://secwatch.observer/filing/0001104659-24-042695.txt

## Key facts
- Earnings Releases
  Annovis Bio, Inc. reported fourth quarter and full year 2023 results: net income $22.2 million.
  - Period: fourth quarter and full year 2023
  - Net income: $22.2 million
  - Result: reported results
  source text: today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/0001104659-24-042695-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.